CytomX Therapeutics (CTMX) Other Accumulated Expenses (2014 - 2026)

CytomX Therapeutics (CTMX) has 13 years of Other Accumulated Expenses data on file, last reported at $1.1 million in Q1 2026.

• Quarterly Other Accumulated Expenses rose 1698.41% year-over-year to $1.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.1 million (up 1698.41% YoY) and the FY2025 annual result came in at $142000.0, down 71.02% from the prior year.
• Other Accumulated Expenses improved to $1.1 million in Q1 2026, from $142000.0 in the prior quarter.
• In the past five years, Other Accumulated Expenses ranged from a high of $1.1 million in Q1 2026 to a low of $63000.0 in Q1 2025.
• A 5-year average of $349176.5 and a median of $292000.0 in 2024 frame the typical range for Other Accumulated Expenses.
• Annual changes were most pronounced in 2025 — Other Accumulated Expenses slumped 86.15% — and 2026, when it surged 1698.41%.
• Tracing CTMX's Other Accumulated Expenses over 5 years: stood at $261000.0 in 2022, then grew by 20.31% to $314000.0 in 2023, then jumped by 56.05% to $490000.0 in 2024, then sank by 71.02% to $142000.0 in 2025, then soared by 697.89% to $1.1 million in 2026.
• The last three Other Accumulated Expenses figures came in at $1.1 million (Q1 2026), $142000.0 (Q4 2025), and $341000.0 (Q3 2025), per Business Quant data.